Kymera Therapeutics, Inc. KYMR Stock Forecast
AI-powered price prediction and analysis for Kymera Therapeutics, Inc. ยท Updated Sep 23, 2026
See KYMR's Exact Price Target
Create a free account and follow this stock to unlock its full AI forecast โ 3 stocks free.
Sign Up Free with GooglePrice Chart
Key Statistics
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) operates in the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. .
Latest News
Where KYMR sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | Ticker | AI Signal | Market Cap | P/E |
|---|---|---|---|---|
| Kymera Therapeutics, Inc. | KYMR | โโ% | $10.15B | -x |
| Amgen Inc | AMGN | โโ% | $221.79B | 25.4x |
| Gilead Sciences, Inc. | GILD | โโ% | $189.30B | -x |
| Moderna, Inc. | MRNA | โโ% | $72.88B | -x |
| Argenx Se | ARGX | โโ% | $59.64B | -x |
| Revolution Medicines, Inc. | RVMD | โโ% | $41.32B | -x |
| Biogen Inc. | BIIB | โโ% | $33.27B | 23.6x |
| Biontech Se | BNTX | โโ% | $25.51B | -x |
| Mesoblast Ltd | MESO | โโ% | $20.65B | -x |
| Neurocrine Biosciences Inc | NBIX | โโ% | $14.46B | 20.5x |
| Exelixis, Inc. | EXEL | โโ% | $14.41B | -x |
| Halozyme Therapeutics, Inc. | HALO | โโ% | $13.07B | 31.6x |
| Bio-Techne Corp | TECH | โโ% | $11.36B | 62.5x |
| Twist Bioscience Corp | TWST | โโ% | $10.40B | -x |
| Krystal Biotech, Inc. | KRYS | โโ% | $10.39B | 43.0x |
| Repligen Corp | RGEN | โโ% | $10.20B | 245.5x |
| Immunitybio, Inc. | IBRX | โโ% | $9.85B | -x |
| Qiagen N.V. | QGEN | โโ% | $9.48B | -x |
| Vaxcyte, Inc. | PCVX | โโ% | $8.78B | -x |
| Immunovant, Inc. | IMVT | โโ% | $7.70B | -x |
| Cg Oncology, Inc. | CGON | โโ% | $6.89B | -x |
| Scholar Rock Holding โฆ | SRRK | โโ% | $5.87B | -x |
| Crispr Therapeutics Ag | CRSP | โโ% | $5.71B | -x |
| Iovance Biotherapeutics, Inc. | IOVA | โโ% | $4.82B | -x |
| Adaptive Biotechnologies Corp | ADPT | โโ% | $4.48B | -x |
| Relay Therapeutics, Inc. | RLAY | โโ% | $3.99B | -x |
| Dbv Technologies S.A. | DBVT | โโ% | $3.74B | -x |
| Denali Therapeutics Inc. | DNLI | โโ% | $3.45B | -x |
| Tarsus Pharmaceuticals, Inc. | TARS | โโ% | $3.40B | -x |
| Beam Therapeutics Inc. | BEAM | โโ% | $2.68B | -x |
| Scinai Immunotherapeutics Ltd. | SCNI | โโ% | $2.34B | -x |
| Biocryst Pharmaceuticals Inc | BCRX | โโ% | $2.24B | -x |
| Adma Biologics, Inc. | ADMA | โโ% | $2.20B | 13.0x |
| Recursion Pharmaceuticals, Inc. | RXRX | โโ% | $2.13B | -x |
| Kodiak Sciences Inc. | KOD | โโ% | $2.12B | -x |
| Vericel Corp | VCEL | โโ% | $2.03B | 83.6x |
| Vir Biotechnology, Inc. | VIR | โโ% | $1.84B | -x |
| Alvotech | ALVO | โโ% | $1.82B | -x |
| Hemab Therapeutics Holdings, โฆ | COAG | โโ% | $1.79B | -x |
| Novavax Inc | NVAX | โโ% | $1.79B | -x |
| Immunocore Holdings Plc | IMCR | โโ% | $1.67B | -x |
| Taysha Gene Therapies, โฆ | TSHA | โโ% | $1.64B | -x |
| Maze Therapeutics, Inc. | MAZE | โโ% | $1.58B | -x |
| Cullinan Therapeutics, Inc. | CGEM | โโ% | $1.39B | -x |
| Vor Biopharma Inc. | VOR | โโ% | $1.30B | -x |
| Replimune Group, Inc. | REPL | โโ% | $1.21B | -x |
| Immatics N.V. | IMTX | โโ% | $1.19B | -x |
| Meiragtx Holdings Plc | MGTX | โโ% | $1.19B | 15.0x |
| Zura Bio Ltd | JATT | โโ% | $1.17B | -x |
| Valneva Se | VALN | โโ% | $1.15B | -x |
| Odyssey Therapeutics, Inc. | ODTX | โโ% | $1.12B | -x |
| Monte Rosa Therapeutics, โฆ | GLUE | โโ% | $1.07B | -x |
| Sana Biotechnology, Inc. | SANA | โโ% | $928M | -x |
| Solid Biosciences Inc. | SLDB | โโ% | $916M | -x |
| Candel Therapeutics, Inc. | CADL | โโ% | $907M | -x |
| 4d Molecular Therapeutics, โฆ | FDMT | โโ% | $877M | -x |
| Aura Biosciences, Inc. | AURA | โโ% | $669M | -x |
| Prime Medicine, Inc. | PRME | โโ% | $642M | -x |
| Ginkgo Bioworks Holdings, โฆ | DNA | โโ% | $631M | -x |
| Allogene Therapeutics, Inc. | ALLO | โโ% | $591M | -x |
FAQ
-
Is Kymera Therapeutics, Inc. a good stock to buy?
Our AI analyzes Kymera Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
-
How accurate are Kymera Therapeutics, Inc. predictions?
A per-ticker accuracy statistic for KYMR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
-
How often are forecasts updated?
Kymera Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 23, 2026.
Ready to invest smarter?
Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Kymera Therapeutics, Inc.?
View full institutional-grade analysis on Intratio โAI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.